Lupin shares fall 4% after USFDA issues Form 483 for Pithampur plant

Lupin shares fall 4% after USFDA issues Form 483 for Pithampur plant

By, Admin 4 March 2023

Shares of Lupin were in focus today after US Food and Drug Administration (USFDA) issued a Form 483 with ten observations after inspecting its Pithampur Unit-2 manufacturing facility. Lupin shares plunged 3.73% to Rs 628.1 against the previous close of Rs 652.45 on BSE. Market cap of the firm fell to Rs 29,118 crore. Total 0.45 lakh shares of the firm changed hands amounting to a turnover of Rs 2.85 crore on BSE. Earlier, the stock opened lower at Rs 641.10. Stock of Lupin has fallen 14.31 per cent in a year and lost 12.77 per cent in 2023. The share hit a 52-week high of Rs 798.90 on April 5, 2022 and a 52-week low of Rs 583.05 on May 25, 2022. In terms of technicals, the relative strength index (RSI) of Lupin stock stands at 44.3, signaling it's neither trading in the overbought nor in the oversold zone. The stock has a beta of 0.8, indicating low volatility in a year. Lupin shares are trading lower than the 5 day, 20 day, 50 day, 100 day and 200 day moving averages. The inspection was done from March 21 to March 29, 2023. The inspection closed with issuance of a Form-483 with ten observations, Lupin said in a regulatory filing.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!